PPARG and systemic sclerosis: Additionally, we observed that the PPARγ agonist rosiglitazone activated MMP-1 and reduced collagen type I in SSc-ILD fibroblasts derived from white subjects; however, it had no effect on MMP-1 and collagen type I in SSc-ILD fibroblasts from black patients.